~~<i id='D8F426C366'><strike id='D8F426C366'><tt id='D8F426C366'><pre id='D8F426C366'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

focus

author：fashion 2025-10-02 20:47:36 - browse：374

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Type 2 diabetes prevention programs work at large scale: study

hotspot

focus

hotspot

entertainment

focus

entertainment

PresidentBidenonFridayrolledoutanewsetofinitiativestoreducehealthcarecosts,includingacrackdownonscam

WSS

Biden launches a new push to limit health care costs

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Experimental asthma app from Apple and Anthem shows promise

Publishing genetic code of viruses could cause disaster

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Today's health inequities arise from racist U.S. history, say experts

explore

focus

hotspot

Medical leaders decry Supreme Court decision on affirmative action

It's time to get medical device identifiers over the finish line

Cancer drug shortages should be causing more outrage

What to know about OceanGate, the company behind the missing Titanic submersible

Duchenne breakthrough therapy leaves behind pioneering families

What is STAT's opinion section for?

Virginia high school admissions case could be legal follow

Publishing genetic code of viruses could cause disaster

Medical leaders decry Supreme Court decision on affirmative action

Study: Pain burden is higher in Black NFL players than white ones

focus

How state and local governments are sidelining science

Healthy food access boosts outcomes in two studies

What health policies could hitch a ride on a spending bill?

Biden launches a new push to limit health care costs

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

What is STAT's opinion section for?

hotspot

entertainment

focus

entertainment